Table 4

Sensitivity analyses of efficacy of prucalopride in chronic idiopathic constipation.

	Number of studies	Number of subjects	RR of failure to respond to therapy	95% CI	I² value	Number needed to treat	95% CI
All studies	7	2639	0.82	0.76 to 0.88	60%	6	5 to 9
Risk of bias of trials
Low	3	1564	0.84	0.79 to 0.89	29%	7	5 to 10
High	4	1075	0.75	0.61 to 0.92	77%	5	3 to 11
Definition of CIC
Rome II criteria	6	2562	0.84	0.81 to 0.88	13%	7	6 to 9
Other criteria	1	77	0.36	0.20 to 0.64	N/A	2	1.5 to 4
Duration of therapy
≤4 weeks	4	662	0.73	0.60 to 0.90	64%	4	3 to 10
>4 weeks	3	1977	0.85	0.81 to 0.90	42%	8	6 to 11
Definition of response to therapy
≥3 CSBMs per week	5	2509	0.84	0.80 to 0.88	28%	7	6 to 9
Other definition	2	130	0.55	0.24 to 1.25	84%	N/A	N/A
Dose of prucalopride used
1 mg od	3	319	0.68	0.46 to 1.00	82%	N/A	N/A
2 mg od	5	1560	0.85	0.80 to 0.90	18%	8	6 to 11
4 mg od	6	1615	0.83	0.77 to 0.90	52%	6	5 to 11

N/A, not applicable; CIC, chronic idiopathic constipation; CSBM, complete spontaneous bowel movement; od, once daily.